**Core Concept**
Sodium valproate is a first-line antiepileptic medication for various types of seizures, but its use during pregnancy is associated with a higher risk of congenital malformations and developmental delays. The goal is to balance seizure control with the potential risks to the fetus.

**Why the Correct Answer is Right**
In a pregnant patient with a history of juvenile myoclonic epilepsy, the primary concern is maintaining seizure control while minimizing fetal exposure to teratogenic medications. Sodium valproate monotherapy is often continued in the first trimester due to its effectiveness, but as the pregnancy advances, adjustments may be necessary. In the second and third trimesters, alternative antiepileptic drugs (AEDs) with a more favorable fetal safety profile, such as lamotrigine or leveiracetam, may be considered in conjunction with sodium valproate or as a replacement.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because abruptly discontinuing sodium valproate in a pregnant patient with a history of juvenile myoclonic epilepsy may lead to breakthrough seizures, which can have adverse effects on both the mother and the fetus.

**Option B:** This option is incorrect because lamotrigine monotherapy may not be sufficient for controlling seizures in patients with juvenile myoclonic epilepsy, and its use may require careful monitoring of blood levels and potential interactions with other medications.

**Option C:** This option is incorrect because valproic acid (sodium valproate) is a known teratogen, and its use during pregnancy is associated with a higher risk of congenital malformations and developmental delays.

**Option D:** This option is incorrect because leveiracetam (levetiracetam) may not be sufficient as a monotherapy for controlling seizures in patients with juvenile myoclonic epilepsy, and its use may require careful monitoring of blood levels and potential interactions with other medications.

**Clinical Pearl / High-Yield Fact**
When adjusting antiepileptic regimens in pregnant patients, it is essential to consider the specific type of epilepsy, the patient's seizure history, and the potential risks and benefits of alternative medications. A multidisciplinary approach involving neurologists, obstetricians, and pharmacists is often necessary to ensure optimal seizure control while minimizing fetal exposure to teratogenic medications.

**Correct Answer: C. Continue sodium valproate in conjunction with lamotrigine or leveiracetam, or consider an alternative AED with a more favorable fetal safety profile.**